|
|
Volumn 14, Issue 1, 1999, Pages 1-4
|
|
Herceptin®: Breaking new ground
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
CANCER ANTIBODY;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
TUMOR PROTEIN;
BREAST CANCER;
CELLULAR DISTRIBUTION;
DRUG APPROVAL;
DRUG SCREENING;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
GENE OVEREXPRESSION;
HUMAN;
IMMUNOHISTOCHEMISTRY;
MEDICAL SOCIETY;
ONCOGENE;
PRIORITY JOURNAL;
UNITED STATES;
ANIMAL;
BIOSYNTHESIS;
BREAST TUMOR;
CLINICAL TRIAL;
DRUG DESIGN;
EXPERIMENTAL NEOPLASM;
FEMALE;
GENE EXPRESSION REGULATION;
GENETICS;
HEALTH CARE ORGANIZATION;
IMMUNOLOGY;
PHYSIOLOGY;
PROTO ONCOGENE;
PUBLIC RELATIONS;
TRANSGENIC ANIMAL;
ANIMALS;
ANIMALS, GENETICALLY MODIFIED;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
BREAST NEOPLASMS;
CLINICAL TRIALS;
DRUG DESIGN;
FEMALE;
GENE EXPRESSION REGULATION, NEOPLASTIC;
GENES, ERBB-2;
HUMANS;
INTERINSTITUTIONAL RELATIONS;
MAMMARY NEOPLASMS, EXPERIMENTAL;
NATIONAL INSTITUTES OF HEALTH (U.S.);
NEOPLASM PROTEINS;
RECEPTOR, ERBB-2;
SOCIETIES, MEDICAL;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0032586391
PISSN: 10849785
EISSN: None
Source Type: Journal
DOI: 10.1089/cbr.1999.14.1 Document Type: Editorial |
|
Times cited : (6)
|
|
References (14)
|
